Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LBH589

Known as: (2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide, LBH 589, NVP-LBH589 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
BACKGROUND Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
LAQ824 and LBH589 (panobinostat) are histone deacetylase inhibitors (HDACi) developed as cancer therapeutics and we have used the… Expand
  • table 1
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Lung cancer is the leading cause of cancer deaths in the United States. Current therapies are inadequate. Histone deacetylase… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Multiple myeloma represents an incurable disease, for which development of new therapies is required. Here, we report the effect… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In… Expand
  • table 2
  • figure 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Histone deacetylase (HDAC) inhibitors have shown cytotoxicity as single agents in preclinical studies for multiple myeloma (MM… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Histone deacetylases (HDAC) have been identified as therapeutic targets due to their regulatory function in DNA structure and… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Present studies show that LBH589, a novel cinnamic hydroxamic acid analog histone deacetylase inhibitor, induces acetylation of… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce… Expand
Is this relevant?